Monoclonal Antibody Bentracimab Shown to Reverse Antiplatelet Effect of Brilinta | ACC 2025; A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding

Media coverage

• Title	Monoclonal Antibody Bentracimab Shown to Reverse Antiplatelet Effect of Brilinta | ACC 2025; A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding
  Media name/outlet	Managed Healthcare Executive (MJH)
  Country/Territory	United States
  Date	1/04/25
  Persons	Deepak L. Bhatt